Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Abstract
Optimal cytoreduction to no residual disease (R0) correlates with improved disease outcome for high-grade serous ovarian cancer (HGSOC) patients. Treatment of HGSOC patients with neoadjuvant chemotherapy, however, may select for tumor cells harboring alterations in hallmark cancer pathways including metastatic potential. This study assessed this hypothesis by performing proteomic analysis of matched, chemotherapy naïve and neoadjuvant chemotherapy (NACT)-treated HGSOC tumors obtained from patients who had suboptimal (R1, n = 6) versus optimal (R0, n = 14) debulking at interval debulking surgery (IDS).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 04, 2022
- Source ID
- 10.1186/s12014-022-09372-y
Entities
People
- Brian L. Hood
- Christine Rojas
- Cuauhtemoc Magana
- Emily R. Penick
- G. Larry Maxwell
- Guisong Wang
- Kathleen M Darcy
- Kelly Conrads
- Ming Zhou
- Nicholas W Bateman
- Niyati Parikh
- Paulette Mhawech-fauceglia
- Thomas P Conrads
- Ying Huang
- Yovanni Casablanca
Organizations
- Uniformed Services University of the Health Sciences